Active Ingredient(s): Selpercatinib
FDA Approved: * May 8, 2020
Pharm Company: * LOXO ONCOLOGY INC
Category: Cancer

Selpercatinib, sold under the brand name Retevmo, is a medication for the treatment of non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET or "rearranged during transfection").[3][1] It is taken by mouth.[1] The most common side effects include changes in laboratory tests (including increased liver enzymes, increased blood ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Retevmo 80 mg Oral Capsule
NDC: 0002-2980
Eli Lilly and Company
Retevmo 40 mg Oral Capsule
NDC: 0002-3977
Eli Lilly and Company